Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Farmers Insurance
Fuji
UBS
McKinsey
Medtronic

Generated: July 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,921,326

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,921,326
Title:Sustained-release composition and method for producing the same
Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.
Inventor(s): Futo; Tomomichi (Osaka, JP), Saito; Kazuhiro (Osaka, JP), Hoshino; Tetsuo (Osaka, JP), Hori; Masuhisa (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/312,751
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,921,326
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 8,921,326

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-003 Jun 17, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y PALLIATIVE TREATMENT OF PROSTATE CANCER ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,921,326

PCT Information
PCT FiledDecember 17, 2007PCT Application Number:PCT/JP2007/074617
PCT Publication Date:June 26, 2008PCT Publication Number: WO2008/075762

International Family Members for US Patent 8,921,326

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 064381 ➤ Try a Free Trial
Australia 2007335406 ➤ Try a Free Trial
Brazil PI0720582 ➤ Try a Free Trial
Canada 2671670 ➤ Try a Free Trial
Chile 2007003658 ➤ Try a Free Trial
China 101563068 ➤ Try a Free Trial
Colombia 6180498 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
Merck
Federal Trade Commission
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.